Skip to main content
Biocartis Group NV logo

Biocartis Group NV — Investor Relations & Filings

Ticker · BCART ISIN · BE0974281132 LEI · 549300J4HOJL5KG8HY54 BR Manufacturing
Open in API
Filings indexed 636 across all filing types
Latest filing 2015-10-20 Share Issue/Capital Cha…
Country BE Belgium
Listing BR BCART

About Biocartis Group NV

https://www.biocartis.com/en

Biocartis Group NV is a molecular diagnostics company that develops and commercializes its proprietary Idylla™ platform. This fully automated, sample-to-result system is designed to provide fast, easy, and actionable molecular diagnostic results, making advanced testing accessible to laboratories of any size. The company's primary focus is in the field of oncology, offering a menu of tests that support the diagnosis and treatment of various cancers, including lung, colorectal, melanoma, and breast cancer. Biocartis aims to enable personalized medicine for patients by providing universal access to molecular testing. The company also collaborates with pharmaceutical partners in the development of companion diagnostics.

Recent filings

Filing Released Lang Actions
20151021_Outstanding Shares Oct 2015_ENG_FINAL.pdf
Share Issue/Capital Change Classification · 98% confidence The document is titled "DISCLOSURE OF OUTSTANDING VOTING SECURITIES" and explicitly states that new shares were issued due to stock option exercises. It then details the resulting changes to the total outstanding share capital, voting securities, and potential future issuances based on outstanding options and warrants. This content directly relates to changes in the company's capital structure and share count, which aligns with the definition of a Share Issue/Capital Change announcement. It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), but a specific disclosure about share capital changes. Therefore, the appropriate code is SHA.
2015-10-20 English
20151021_Outstanding Shares Oct 2015_NL_FINAL.pdf
Share Issue/Capital Change Classification · 98% confidence The document is titled "OPENBAARMAKING VAN UITSTAANDE STEMRECHTVERLENENDE EFFECTEN" (Disclosure of Outstanding Voting Securities) and explicitly states that 38,500 new shares were issued following the exercise of stock options. It then details the resulting changes to the total outstanding share capital, total outstanding shares, and potential future shares issuable under various plans (2013 Plan, 2015 Plan, WHC Warrants, and a conversion agreement with Philips). This content directly relates to changes in the company's share structure and capital base due to the issuance of new shares/options being exercised. This aligns perfectly with the definition of 'Share Issue/Capital Change' (SHA). It is not an earnings release (ER), an interim report (IR), or a general regulatory filing (RNS), as it concerns a specific capital event.
2015-10-20 Dutch
Press Release Results H1 2015 FINAL_eng.pdf
Earnings Release Classification · 95% confidence The document is a press release titled 'BIOCARTIS ANNOUNCES H1 2015 RESULTS AND STRENGTHENING OF MANAGEMENT TEAM'. It provides a summary of financial highlights, operational progress, and management changes for the first half of 2015. While it contains financial data, it is structured as a press release (Earnings Release) rather than a full statutory interim report. It explicitly mentions that a glossary of terms can be found in the 'interim financial report 2015', implying this document is the initial announcement of those results. H1 2015
2015-09-10 English
Persbericht Resultaten H1 2015 FINAL_nl.pdf
Earnings Release Classification · 99% confidence The document is explicitly titled as a 'PERSBERICHT' (Press Release) announcing 'HALFJAARRESULTATEN 2015' (Half-Year Results 2015) and management team strengthening. It details operational highlights (sales, menu development) and financial highlights (revenue, cash position) for the first half of the year, concluding with a CEO quote. This structure perfectly matches the definition of a comprehensive financial report for a period shorter than a year, which is classified as an Interim / Quarterly Report (IR). Although it is a press release announcing the results, the content provided is substantial and detailed, making it the report itself rather than just a brief announcement of publication (RPA). The mention of IAS 34 'Tussentijdse Financiële Verslaggeving' confirms its nature as an interim financial report. H1 2015
2015-09-10 Dutch
Biocartis Group NV Financial Report H1 2015 FINAL.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'BIOCARTIS GROUP NV FINANCIAL REPORT H1 2015'. It contains a message from the CEO, a responsibility statement, a business review, and a detailed table of contents listing condensed consolidated interim financial statements (balance sheet, income statement, cash flow, etc.) for the period ended 30 June 2015. This is a comprehensive interim financial report, not an announcement or a summary, fitting the definition of an Interim/Quarterly Report (IR). H1 2015
2015-09-10 English
Biocartis Groep NV Financieel Verslag H1 2015 FINAL.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'FINANCIEEL VERSLAG H1 2015' (Financial Report H1 2015) for Biocartis Groep NV. It contains a comprehensive set of financial statements, including a consolidated balance sheet, income statement, cash flow statement, and detailed notes to the financial statements for the six-month period ending June 30, 2015. It also includes a message from the CEO and an overview of business operations. Since it covers a period shorter than a full fiscal year and contains substantive financial data and analysis, it is classified as an Interim/Quarterly Report. H1 2015
2015-09-10 Dutch

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.